KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) EPS (Weighted Average and Diluted) (2016 - 2025)

Eli Lilly (LLY) has disclosed EPS (Weighted Average and Diluted) for 14 consecutive years, with $7.39 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 51.43% year-over-year to $7.39, compared with a TTM value of $22.95 through Dec 2025, up 95.99%, and an annual FY2025 reading of $22.95, up 95.99% over the prior year.
  • EPS (Weighted Average and Diluted) was $7.39 for Q4 2025 at Eli Lilly, up from $6.21 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $7.39 in Q4 2025 and bottomed at -$0.06 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is $2.67, with a median of $2.02 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 103.75% in 2023, then soared 1883.33% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at $1.89 in 2021, then grew by 13.23% to $2.14 in 2022, then rose by 13.08% to $2.42 in 2023, then soared by 101.65% to $4.88 in 2024, then surged by 51.43% to $7.39 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for LLY at $7.39 in Q4 2025, $6.21 in Q3 2025, and $6.29 in Q2 2025.